Nicolas Frances

624 total citations
22 papers, 436 citations indexed

About

Nicolas Frances is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nicolas Frances has authored 22 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nicolas Frances's work include Monoclonal and Polyclonal Antibodies Research (5 papers), Cancer Treatment and Pharmacology (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Nicolas Frances is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), Cancer Treatment and Pharmacology (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Nicolas Frances collaborates with scholars based in Switzerland, France and Germany. Nicolas Frances's co-authors include Athanassios Iliadis, Aurore Blesius, Cédric Mercier, Florence Duffaud, Joseph Ciccolini, Thierry Lavé, Jean‐François Seitz, Laëtitia Dahan, Christophe Meille and Laurent Claret and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Nicolas Frances

20 papers receiving 425 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicolas Frances Switzerland	11	221	191	78	71	63	22	436
Nicole Kelly United States	4	251 1.1×	154 0.8×	37 0.5×	167 2.4×	22 0.3×	5	601
Agnese Antognoli Italy	10	148 0.7×	109 0.6×	24 0.3×	23 0.3×	57 0.9×	19	352
Musalula Sinkala Zambia	10	188 0.9×	107 0.6×	20 0.3×	122 1.7×	24 0.4×	29	380
Devin Worster United States	4	255 1.2×	153 0.8×	32 0.4×	55 0.8×	16 0.3×	6	410
Mathilde Marchand France	10	65 0.3×	255 1.3×	25 0.3×	50 0.7×	91 1.4×	19	388
Christy Osgood United States	11	132 0.6×	359 1.9×	26 0.3×	102 1.4×	129 2.0×	19	541
Zinnia P. Parra‐Guillén Spain	13	171 0.8×	112 0.6×	15 0.2×	34 0.5×	61 1.0×	38	388
C. Chow United States	9	167 0.8×	260 1.4×	35 0.4×	64 0.9×	30 0.5×	11	434
Marye J. Boers‐Sonderen Netherlands	14	194 0.9×	346 1.8×	26 0.3×	43 0.6×	54 0.9×	43	523
Itziar Irurzun‐Arana Spain	10	210 1.0×	173 0.9×	20 0.3×	25 0.4×	16 0.3×	17	364

Countries citing papers authored by Nicolas Frances

Since Specialization

Citations

This map shows the geographic impact of Nicolas Frances's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Frances with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Frances more than expected).

Fields of papers citing papers by Nicolas Frances

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Frances. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Frances. The network helps show where Nicolas Frances may publish in the future.

Co-authorship network of co-authors of Nicolas Frances

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Frances. A scholar is included among the top collaborators of Nicolas Frances based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Frances. Nicolas Frances is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Parra‐Guillén, Zinnia P., et al.. (2025). Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies. Frontiers in Immunology. 15. 1463915–1463915. 1 indexed citations

Sánchez, Javier, Christina Claus, Christine McIntyre, et al.. (2024). Combining mathematical modeling, in vitro data and clinical target expression to support bispecific antibody binding affinity selection: a case example with FAP-4-1BBL. Frontiers in Pharmacology. 15. 1472662–1472662. 1 indexed citations

Claus, Christina, R. Albrecht, Christine McIntyre, et al.. (2023). A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology. CPT Pharmacometrics & Systems Pharmacology. 12(11). 1804–1818. 2 indexed citations

Frances, Nicolas, Wilhelm Huisinga, Niklas Hartung, et al.. (2023). A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients. CPT Pharmacometrics & Systems Pharmacology. 12(11). 1714–1725. 5 indexed citations

Nicolini, Valeria, Linda Fahrni, Inja Waldhauer, et al.. (2022). Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1. The AAPS Journal. 24(6). 106–106. 3 indexed citations

Frances, Nicolas, Marina Bacac, Katharine Bray‐French, et al.. (2021). Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab. Journal of Pharmaceutical Sciences. 111(4). 1208–1218. 18 indexed citations

Weinzierl, Tina, Nicolas Frances, Sylvia Herter, et al.. (2020). Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining In Vitro Experiments with Systems Modeling. Molecular Cancer Therapeutics. 20(2). 357–366. 16 indexed citations

Frances, Nicolas, et al.. (2020). Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non–Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors. Journal of Pharmacology and Experimental Therapeutics. 375(3). 430–438. 4 indexed citations

Ducray, Patricia Sanwald, Nicolas Frances, Kevin Smart, et al.. (2019). Translational Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling Strategy to Support RG6042 Dose Selection in Huntington’s Disease (HD) (S16.005). Neurology. 92(15_supplement). 6 indexed citations

10.

Guenther, Andreas, Birgit Jaber, Paul Jordan, et al.. (2018). A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. British Journal of Clinical Pharmacology. 85(1). 181–193. 74 indexed citations

11.

Frances, Nicolas, et al.. (2017). PKPD modeling of acquired resistance to anti-cancer drug treatment. Journal of Pharmacokinetics and Pharmacodynamics. 44(6). 617–630. 14 indexed citations

12.

Frances, Nicolas, et al.. (2016). Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib. Molecular Cancer Therapeutics. 15(12). 3110–3119. 10 indexed citations

13.

Caruso, Antonello, Nicolas Frances, Christophe Meille, et al.. (2014). Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development. Journal of Pharmacological and Toxicological Methods. 70(1). 73–85. 25 indexed citations

14.

Frances, Nicolas, et al.. (2012). Progress in Strategies for Dosage Regimen Individualization. Current Topics in Medicinal Chemistry. 12(15). 1669–1677. 2 indexed citations

15.

Frances, Nicolas, et al.. (2012). Optimize Administration Protocol of Capecitabine Plus Docetaxel Combination in Metastatic Breast Cancer Patients. Current Topics in Medicinal Chemistry. 12(15). 1665–1668.

16.

Frances, Nicolas, Laurent Claret, René Bruno, & Athanassios Iliadis. (2011). Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 68(6). 1413–1419. 31 indexed citations

17.

Yang, Chen, Joseph Ciccolini, Aurore Blesius, et al.. (2010). DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemotherapy and Pharmacology. 67(1). 49–56. 59 indexed citations

18.

Ciccolini, Joseph, Laëtitia Dahan, Nicolás André, et al.. (2009). Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies. Journal of Clinical Oncology. 28(1). 160–165. 86 indexed citations

19.

Meille, Christophe, Athanassios Iliadis, Dominique Barbolosi, Nicolas Frances, & Gilles Freyer. (2008). An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics. 35(6). 619–633. 22 indexed citations

20.

Mercier, Cédric, Charlotte Dupuis, Aurore Blesius, et al.. (2008). Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemotherapy and Pharmacology. 63(6). 1177–1180. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact